NASDAQ
3.64USD
-0.02 (-0.55%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
216M
P/E
—
EPS
—
Beta
0.81
52W range
2.77-15.55
Day range
3.52–3.69
Open
3.61
Prev close
3.66
Volume
1.2M
Avg volume
2.6M
Dividend
0.46
IPO
2022-03-22
https://www.prnewswire.com/news-releases/adma-investor-alert-adma-biologics-inc-adma-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-hbss-302838080.html · 7/29/2026-0.80
https://www.prnewswire.com/news-releases/embc-investor-alert-embecta-corp-embc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-hagens-berman-302838076.html · 7/29/2026-1.00
https://www.newsfilecorp.com/release/306465/EMBC-DEADLINE-ALERT-Faruqi-Faruqi-LLP-Reminds-Embecta-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-17-2026 · 7/26/2026-1.00
https://www.globenewswire.com/news-release/2026/07/20/3329405/673/en/LUCID-DEADLINE-ROSEN-RECOGNIZED-INVESTOR-COUNSEL-Encourages-Lucid-Group-Inc-Investors-to-Secure-Counsel-Before-Important-July-28-Deadline-in-Securities-Class-Action-LCID.html · 7/20/2026
https://www.newsfilecorp.com/release/305554/EMBC-SHAREHOLDER-ACTION-REMINDER-Faruqi-Faruqi-LLP-Reminds-Embecta-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-17-2026 · 7/18/2026-1.00
https://www.prnewswire.com/news-releases/embc-investor-deadline-embecta-corp-investors-with-substantial-losses-have-opportunity-to-lead-investor-class-action-lawsuit---hbss-302825725.html · 7/15/2026-1.00
https://www.globenewswire.com/news-release/2026/07/10/3325701/32716/en/Embecta-Corp-EMBC-Faces-Securities-Class-Action-Over-Alleged-Concealed-Material-Risks-to-Pen-Needle-Revenue-HBSS.html · 7/10/2026-1.00
https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-over-alleged-concealed-material-risks-to-pen-needle-revenue-hbss-302820081.html · 7/8/2026-1.00
https://www.globenewswire.com/news-release/2026/07/03/3321968/32716/en/Embecta-Corp-EMBC-Faces-Securities-Class-Action-for-Allegedly-Concealing-Competitive-Threats-to-Pen-Needle-Business-HBSS.html · 7/3/2026-1.00
https://www.globenewswire.com/news-release/2026/07/03/3321965/32716/en/Erasca-Inc-ERAS-Faces-Securities-Class-Action-Amid-Patient-Death-Intellectual-Property-Questions-2-8-Billion-Market-Cap-Loss-HBSS.html · 7/3/2026-0.50
https://www.globenewswire.com/news-release/2026/06/25/3317241/32716/en/Embecta-Corp-EMBC-Faces-Securities-Class-Action-for-Allegedly-Concealing-Competitive-Threats-to-Pen-Needle-Business-Hagens-Berman.html · 6/25/2026-1.00
https://www.globenewswire.com/news-release/2026/06/25/3317237/32716/en/Erasca-Inc-ERAS-Faces-Securities-Class-Action-Amid-Patient-Death-Intellectual-Property-Questions-2-8-Billion-Market-Cap-Loss-Hagens-Berman.html · 6/25/2026-1.00
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
